Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Value of systematic genetic screening of patients with amyotrophic lateral sclerosis

Open access

Abstract

Objective: The clinical utility of routine genetic sequencing in amyotrophic lateral sclerosis (ALS) is uncertain. Our aim was to determine whether routine targeted sequencing of 44 ALS-relevant genes would have a significant impact on disease subclassification and clinical care. Methods: We performed targeted sequencing of a 44-gene panel in a prospective case series of 100 patients with ALS recruited consecutively from the Sheffield Motor Neuron Disorders Clinic, UK. All participants were diagnosed with ALS by a specialist Consultant Neurologist. 7/100 patients had familial ALS, but the majority were apparently sporadic cases. Results: 21% of patients with ALS carried a confirmed pathogenic or likely pathogenic mutation, of whom 93% had no family history of ALS. 15% met the inclusion criteria for a current ALS genetic-therapy trial. 5/21 patients with a pathogenic mutation had an additional variant of uncertain significance (VUS). An additional 21% of patients with ALS carried a VUS in an ALS-associated gene. Overall, 13% of patients carried more than one genetic variant (pathogenic or VUS). Patients with ALS carrying two variants developed disease at a significantly earlier age compared with patients with a single variant (median age of onset=56 vs 60 years, p=0.0074). Conclusions: Routine screening for ALS-associated pathogenic mutations in a specialised ALS referral clinic will impact clinical care in 21% of cases. An additional 21% of patients have variants in the ALS gene panel currently of unconfirmed significance after removing non-specific or predicted benign variants. Overall, variants within known ALS-linked genes are of potential clinical importance in 42% of patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jnnp-2020-325014

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Clinical screening of all patients with ALS identifies pathogenic, likely pathogenic and variants of uncertain significance (VUS). (A) The 44 genes covered by the clinical ALS panel (42 profiled by next-generation sequencing and 2 by PCR). Those genes in which pathogenic (red), likely pathogenic variants (orange) or VUS (blue) were identified after filtering. No pathogenic variants or VUS were found in the genes depicted in the white boxes. Background colour of the box represents the most severe variant found in that gene. (B) Schematic of our variant analysis and filtering process. (C) Counts of reportable (red) and variants of unknown significance in ALS genes in the Sheffield AMBRoSIA cohort. (D) Five clinically reportable variants in SOD1. (E) 4 Variants of unknown significance were discovered in SPG11. Interestingly, 3 of these cluster in the C-terminal domain. Benign and likely benign mutations are conversely distributed throughout the protein. Protein domain figures created using ProteinPaint (https://pecan.stjude.cloud/proteinpaint).
Figure 1 Clinical screening of all patients with ALS identifies pathogenic, likely pathogenic and variants of uncertain significance (VUS). (A) The 44 genes covered by the clinical ALS panel (42 profiled by next-generation sequencing and 2 by PCR). Those genes in which pathogenic (red), likely pathogenic variants (orange) or VUS (blue) were identified after filtering. No pathogenic variants or VUS were found in the genes depicted in the white boxes. Background colour of the box represents the most severe variant found in that gene. (B) Schematic of our variant analysis and filtering process. (C) Counts of reportable (red) and variants of unknown significance in ALS genes in the Sheffield AMBRoSIA cohort. (D) Five clinically reportable variants in SOD1. (E) 4 Variants of unknown significance were discovered in SPG11. Interestingly, 3 of these cluster in the C-terminal domain. Benign and likely benign mutations are conversely distributed throughout the protein. Protein domain figures created using ProteinPaint (https://pecan.stjude.cloud/proteinpaint).CC BY-NC · PubMed Central
Figure 2 Increased mutation burden is associated with earlier age at onset. (A) Details of patients with two or more pathogenic, likely pathogenic or variants of uncertain significance (VUS) (n=13). (B) The number of pathogenic, likely pathogenic and VUS in each patient in the study. (C) Cumulative event plot showing those patients with two or more pathogenic, likely pathogenic or VUS have a significantly earlier age of onset.
Figure 2 Increased mutation burden is associated with earlier age at onset. (A) Details of patients with two or more pathogenic, likely pathogenic or variants of uncertain significance (VUS) (n=13). (B) The number of pathogenic, likely pathogenic and VUS in each patient in the study. (C) Cumulative event plot showing those patients with two or more pathogenic, likely pathogenic or VUS have a significantly earlier age of onset.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Research works printed but not linked: 1

  1. Karczewski KJ , Francioli LC , Tiao G , et al . Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. BioRxiv 2019.

Cited by

See all 116

Metadata

Authors
Shepheard, S. R., Parker, M. D., Cooper-Knock, J., Verber, N. S., Tuddenham, L., Heath, P., Beauchamp, N., Place, E., Sollars, E. S. A., Turner, M. R., Malaspina, A., Fratta, P., Hewamadduma, C., Jenkins, T. M., McDermott, C. J., Wang, D., Kirby, J., & Shaw, P. J.
Affiliations
  • University of Sheffield (GB)
  • Sheffield Children's NHS Foundation Trust (GB)
  • University of Oxford (GB)
  • Queen Mary University of London (GB)
  • UCL Queen Square Institute of Neurology (GB)
  • Sheffield Teaching Hospitals NHS Foundation Trust (GB)
Corresponding author
Shaw, Pamela J
Venue
Journal of Neurology, Neurosurgery & Psychiatry
Publisher
BMJ
Published
2021-02-14
Volume
92
Issue
5
Pages
510-518
ISSN
  • 0022-3050 (ISSN-L)
  • 1468-330X
OpenAlex
W3114107609
Cited by
116
References
42
Citations by year
2026: 15 · 2025: 16 · 2024: 22 · 2023: 21 · 2022: 29 · 2021: 13
FWCI
10.17
Type
journal article
Language
en
Open access
Locations
  • Journal of Neurology Neurosurgery & Psychiatry (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • Lirias (submittedVersion, other-oa)
  • Research Portal (Queen's University Belfast) (submittedVersion, cc-by-nc)
  • OAR@UM (University of Malta) (submittedVersion, other-oa)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • Motor Neurone Disease Association (AMBRoSIA 972-797, NECTAR 974-797)
  • National Institute for Health Research (Senior Investigator NF-SI-0617-10077, Sheffield Biomedical Research Centre IS-BRC-1215-2)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
amyotrophic lateral sclerosis, genetic screening, targeted sequencing, pathogenic variants, variants of uncertain significance, familial ALS, sporadic ALS, age of onset, disease subclassification
MeSH terms
Adult, Aged, Aged, 80 and over, Amyotrophic Lateral Sclerosis, Female, Genetic Testing, Humans, Male, Middle Aged, Mutation, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. https://app.cochat.ai/papers/10.1136/jnnp-2020-325014
The paper
Shepheard, S. R., Parker, M. D., Cooper-Knock, J., Verber, N. S., Tuddenham, L., Heath, P., Beauchamp, N., Place, E., Sollars, E. S. A., Turner, M. R., Malaspina, A., Fratta, P., Hewamadduma, C., Jenkins, T. M., McDermott, C. J., Wang, D., Kirby, J., & Shaw, P. J. (2021). Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2020-325014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.